ETF profile for Tema Heart & Health ETF (HRTS) from the issuer: top holdings, net assets, expense ratio and shares outstanding.
HRTS ETF Profile
| Family: |
Tema |
| Name: |
Tema Heart & Health ETF |
|
|
| Inception Date: |
20-Nov-2023 |
| Termination Date: |
|
| Investment Objective: |
Tema Heart & Health ETF seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to GLP-1 and the treatment of cardiovascular diseases and/or metabolic diseases, as defined by the Centers for Diseases Control and Preventions ("CDC"). GLP-1 (glucagon-like peptide) is a class of drugs that can help manage diabetes and obesity. The Adviser will apply this definition to internal research and analysis based on company disclosure (such as 10-K filings, company presentations, capital markets day presentations) and other publicly available sources (e.g., sell-side research, biotechnology industry publications etc.) to make this assessment. Example companies include large pharmaceutical firms, development-stage biotechnology companies, diagnostic focused businesses with products used to diagnose and/or treat the aforementioned diseases, medical device companies focused on treatment of the aforementioned diseases, and healthcare service providers with a specific strategic focus on helping treat and manage the aforementioned diseases, each providing they meet the aforementioned revenue test. |
|
|
| Prospectus |
|
|
|
| Top 10 Holdings |
|
|
| Eli Lilly & Co |
LLY |
12.1300% |
| Thermo Fisher Scientific Inc |
TMO |
5.3000% |
| Merck & Co Inc |
MRK |
4.5400% |
| Roche Holding AG |
RHHBY |
4.3900% |
| UnitedHealth Group Inc |
UNH |
3.8000% |
| Revolution Medicines Inc |
RVMD |
3.5800% |
| Bridgebio Pharma Inc |
BBIO |
3.3200% |
| Kodiak Sciences Inc |
KOD |
3.3100% |
| Johnson & Johnson |
JNJ |
3.3000% |
| Novo Nordisk A/S |
NOVOB |
3.2300% |
|
Top 10 Holdings Weight: |
46.9% |
| Number of Holdings: |
46 |
| Shares Outstanding: |
1,480,000 |
| Total Net Assets: |
55,914,992 |
| NAV: |
37.79 |
| Net Expense Ratio: |
0.75% |
|
|
| Asset Class: |
Equities (Stocks) |
| Developed or Emerging: |
Developed Market Funds |
| Country: |
|
| Region: |
|
| Strategy: |
|
| Currency: |
|
| Commodity: |
|
| Sector: |
Healthcare |
| Industry: |
|
| Dividend Type: |
|
| Tax Exempt State: |
|
| Maturity Duration: |
|
| Market Cap: |
Broad Market / Multi-Cap |
| Credit Quality: |
|
| Mortgage Bond Types: |
|
| Bond Type: |
|
| Gov't Bond Types: |
|
| Reit Type: |
|
| Leverage Direction/Factor: |
|
| Is Currency Hedged: |
No |
| US or Ex-US: |
Global |
